Skip to content

Tacrolimus Ointment in Oral Lichen Planus

Comparison of Topical Tacrolimus, Triamcinolone and Placebo in the Treatment of Symptomatic Oral Lichen Planus

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01544842
Enrollment
28
Registered
2012-03-06
Start date
2004-08-31
Completion date
2015-07-31
Last updated
2015-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Keywords

Oral lichen planus, Tacrolimus ointment, Triamcinolone paste

Brief summary

The purpose of this study is to compare the effectiveness of topical tacrolimus, triamcinolone and placebo in alleviating signs and symptoms of oral lichen planus (OLP).

Interventions

DRUG0.1 % tacrolimus ointment

applied topically to oral mucosa

DRUG0.1 % triamcinolone paste

applied topically to oral mucosa

DRUGOrabase paste

applied topically to oral mucosa

Sponsors

Kuopio University Hospital
CollaboratorOTHER
University of Oulu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of OLP made by a specialist in oral pathology based on clinical and histopathological features * Clinical score for OLP ≥ 20 at baseline * Symptomatic OLP at baseline * Washout period of 2 weeks * Age over 18

Exclusion criteria

* Pregnant or lactating women * Allergy to tacrolimus or other macrolides * Allergy to other drugs or substances used in the study * Abnormal liver function * Netherton's syndrome * Cyclosporin medication * Other regular medication that could have significant interactions with tacrolimus

Design outcomes

Primary

MeasureTime frameDescription
Change in clinical score for OLP1,2,3,4,5,6,7,8 and 9 weeks, 6 monthsThe clinical score for OLP is a measure designed by the investigators for assessing the clinical extent and type of OLP, and the symptoms experienced by the patient. The value of the score is between 0-120.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026